Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Amortizatization of Intangibles (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Amortizatization of Intangibles for 5 consecutive years, with $153518.0 as the latest value for Q1 2023.

  • On a quarterly basis, Amortizatization of Intangibles fell 40.47% to $153518.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $786972.0, a 22.84% decrease, with the full-year FY2022 number at $891343.0, down 12.07% from a year prior.
  • Amortizatization of Intangibles was $153518.0 for Q1 2023 at Marker Therapeutics, up from $151897.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $259170.0 in Q2 2022 to a low of $44211.0 in Q1 2019.
  • A 5-year average of $166471.4 and a median of $222387.0 in 2022 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: soared 442.56% in 2020, then plummeted 40.59% in 2022.
  • Marker Therapeutics' Amortizatization of Intangibles stood at $46540.0 in 2019, then skyrocketed by 442.56% to $252509.0 in 2020, then grew by 1.26% to $255697.0 in 2021, then tumbled by 40.59% to $151897.0 in 2022, then increased by 1.07% to $153518.0 in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Amortizatization of Intangibles are $153518.0 (Q1 2023), $151897.0 (Q4 2022), and $222387.0 (Q3 2022).